HIKALNSEHikal Limited· PharmaceuticalsHighNegative
Announced Wed, 27 May · 16:12 IST

Hikal Limited has informed the Exchange about Frauds/Default by employees

Fraud ConfirmedRegulatory & Legal View source PDF

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-12.9%1-day move
₹220.99
prior close
₹209.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.2-1.9-2.0-2.9-12.9-13.2-14.8-13.3-14.4-17.8-7.0-3.1
Up moveDown movePending
AI summary

Hikal Limited has disclosed two items. First, the appointment of Mr. Ravi Khadabadi as President-Crop Protection & Specialty Chemicals, who holds advanced degrees from Mumbai and the University of Massachusetts, USA, with extensive experience in Pharma and Specialty Chemicals. Second, and more significant, the company has provided follow-up details on employee irregularities first disclosed in December 2025. The irregularities involved the timing of revenue recognition as of September 30, 2025, specifically the prepone ment of genuine sales. An external expert review concluded the irregularities were limited to this and have been corrected. The employees responsible have been identified and relieved from service. The company states there is no impact on current or previous period financials.

Likely market impact

The employee fraud involving premature revenue recognition is negative but appears contained, with management asserting no financial impact. The firing of involved employees and appointment of an external reviewer shows some accountability. However, any regulatory investigation or penalties from SEBI remain a risk if they determine the disclosure was incomplete.